Official advisory board

We are delighted to announce a new Official Advisory Board for our bioLOGIC events. Unofficially we have always worked with the industry leaders to create the best agendas and source the best speakers. Now we are making it official.

Board members include:

There are still opportunities for you to join our official advisory board. To apply please email joyce.harmon@terrapinn.com

Andrew Sinclair, Co Founder, Managing Director, BioPharm Services	Andrew Sinclair founded BioPharm Services in December 1998 to develop a technology based services business focused on all aspects of biopharmaceuticals manufacturing. The company has developed software tools and databases for economic analysis and optimisation of bioprocesses and manufacturing operations. It also has developed unique insights into the market biomanufacturing market dynamics. Biopharm Services is six years old it has 12 employees based both in the UK and the US. Andrew Sinclair has over 20 years experience within the biopharmaceutical sector working for manufacturing operations (Lonza, Eli Lilly, GlaxoSmithKline) and contractors (Kvaerner, Jacobs engineering).  He has been responsible for design, building and operation of biomanufacturing facilities.   Prior to setting up Biopharm Services Andrew was the Director of Engineering and Logistics and Lonza Biologics.
Dr James Hope, Vice President of Biotechnology, BioProcessors	Prior to joining BioProcessors in 2003, Dr. Hope served from 1992 to 2002 as Senior Vice President of  Product  Development and later Chief Technology Officer at BioTransplant Inc., a biopharmaceutical company focusing on the development of biologics and procedures for the generation of immune tolerance to allo and xenografts. From 1990 to 1992, he served as Executive Director of Operations Technical Support at Serono Laboratories, Inc. From 1986 until 1990, he served as the Director of Production and Bioprocess Development at Invitron Corp., a contract developer and manufacturer of mammalian cell-based biopharmaceuticals.   Dr. Hope received a B.Sc. in Microbiology and Chemistry from the University of Reading (UK) and a Ph.D. in Biochemistry from King's College London(UK).
Dr Barry Holtz, Principal, Holtz BioPharm Consulting	Dr. Holtz is the President and CEO of Inflexion Therapeutics in Little Rock, Arkansas.  Inflexion is a company founded to make monoclonal antibodies for protective therapies. Dr. Holtz is also the principal of Holtz Biopharma Consulting, a firm specializing in biopharmaceuticals development.  Prior to the founding of Inflexion Therapeutics, Dr. Holtz was the Senior Vice President of Biopharmaceutical Development for Large Scale Biology Corporation for 15 years and was an integral member of the management team that took the company from a start-up to a successful public company.   Dr. Holtz was responsible for the product development, clinical development and manufacturing compliance of the company’s proprietary therapeutics portfolio.  These projects included leading the development and manufacturing team that successfully brought a recombinant, plant-made, patient specific vaccine for treatment of indolent Non-Hodgkin’s lymphoma from the bench to human clinical trials.  Dr. Holtz was also responsible for the design, construction and commissioning of the LSBC biopharmaceutical production facility in Owensboro, Kentucky.
Sandra Fox, President, HighTech Business Decisions	Sandra J. Fox is President of HighTech Business Decisions in Moraga, CA. HighTech Business Decisions is a market research company that has tracked the biopharmaceutical contract manufacturing market for nearly 10 years.  Ms. Fox has a Master of Business Administration degree from the University of California at Berkeley, Haas School of Business, and is a Phi Beta Kappa graduate in the life sciences at UC Berkeley. Ms. Fox founded HighTech Business Decisions to help clients determine successful business development strategies through customized market research and analysis.  Since 1997, the company has produced eight major industry reports on biopharmaceutical contract manufacturing, which track capacity, demand, market size, prices paid for outsourced production, contractor capabilities, and the changing technologies in bioprocesses and scale-up production.
Dr Meenu Wadhwa, Group Leader, Cytokine and Growth Factor Group, NIBSC	Meenu Wadhwa is Section Leader for the Cytokines and Growth factors Group in the Division of Biotherapeutics at the National Institute for Biological Standards and Control, United Kingdom. She is responsible for work in the cytokine and growth factor area and has considerable experience in preparation of cytokine standards and/or reference reagents, the development, validation and implementation of cytokine assays and their use in standardization, control and in research. Over the last ten years, her work has focussed on the unwanted immunogenicity of biotherapeutic products. This has involved development of different assays for detection, measurement and characterization of anti-product antibodies and has contributed to a number of important publications. A significant aspect of her work involves close collaboration with a number of research groups and biotechnology companies.
Professor Beate Stern, Associate Professor, Department of Biomedicine, University of Bergen	Beate Stern, PhD, Associate Professor at the Department of Biomedicine, University of Bergen, and Chief Scientific Officer and cofounder of the biotech spin-off company UniTargetingResearch AS, Bergen, Norway. Expertise in molecular biology, cell biology and bioinformatics. Fields of current research interest are DNA mobility and mRNA/protein localisation. Former professional activities include science journalism and former affiliations include the Max Planck Institute of Biochemistry, Martinsried, Germany.
Dr Avinoam Kadouri, CEO, Rainbow Biotechnologies	Dr Kadouri is the chairman of ACTIP European Animal Cell Technology Industrial Platform  and a member of Scientific Advisory Boards of several European and American companies and also a consultant to many biotech companies. Prior to his forming Rainbow Biotechnologies he was bioprocess Technology Development Director, Serono Biotech Center, Vevey, Switzerland. Responsible for the development of new technologies in upstream and downstream to be implemented in process development and in manufacturing and Associate Professor at the Weizmann Institute of Science, Head of cell culture and Biotechnology unit.
Brendan Fish, Director of Bioprocess Sciences, Biopharmaceutical Development, Cambridge Antibody Technology	(1998-Present) Cambridge Antibody Technology. Joined CAT as Head of Downstream Processing in November 1998 and was promoted to Director of Bioprocess Sciences in October 2001.  Currently responsible for all aspects of the development of purification methodologies for all CAT’s products in relation to their use in commercial pharmaceutical processes.  This includes initial design and optimisation, scale-up, process cost modelling, process integration, technology transfer to GMP Production, formulation and delivery and product characterisation.   (1991-1998) Delta Biotechnology Limited. Consulting Scientist. Played a key role in the development of their biotechnology-based products providing expert opinion and strategies for QA, QC, Production, Marketing, Operations, Regulatory Affairs and Engineering on all aspects of Process Development.   (1989-1991) University of Toronto in Canada. Post-doctoral fellowship working in the School of Nutritional Sciences, studying the anti-nutritional effects of lectins in the diet.   Also held posts as a Reseach Assistant and a Medical Laboratory Scientific Officer.